Journal article icon

Journal article

Single-cell transcriptomic landscape deciphers intratumoral heterogeneity and subtypes of acral and mucosal melanoma

Abstract:
Purpose:
To identify the specific intratumoral and microenvironmental heterogeneity of acral (AM) and mucosal melanoma (MM), we aimed to delineate their distinct cellular compositions, evolutionary trajectories, and subtype-specific therapeutic strategies.

Experimental Design:
Single-cell transcriptomic and genomic landscapes were analyzed across 42 melanoma samples (28 AM, 11 MM, and 3 non-acral cutaneous melanoma [CM]), supplemented by in vitro and in vivo validation. Tumor and stromal cells were profiled using scRNA-seq, whole-exome sequencing, and functional assays, including transwell migration, co-culture systems, and xenograft models.

Results:
Tumor cells exhibited divergent evolutionary routes, with MM dominated by MGP⁺/PCOLCE⁺ subpopulations showing high epithelial-to-mesenchymal transition (EMT) potential. MM displayed elevated neutrophil infiltration and CXCL3⁺ tumor-associated macrophages, while AM was enriched with PI16⁺ cancer-associated fibroblasts (CAFs) promoting tumor proliferation. Molecular classification revealed MM subtypes: an antigen-presenting subtype linked to favorable outcomes and a proliferative subtype associated with recurrence. TIGIT⁺ Treg cells were enriched in AM, suggesting targeted inhibition potential. Genomic analysis connected BRAF/NRAS mutations to ALDOA⁺ stem-like tumor cells and identified PTGDS as a therapeutic target in triple-WT melanomas.

Conclusions:
Our study provides a comprehensive comparison of AM and MM, uncovering subtype-specific stromal-immune interactions and molecular programs. The findings highlight actionable targets (e.g., TIGIT in AM, CXCL3⁺ macrophages in MM) and propose a framework for precision therapies, biomarker-driven trials, and risk stratification to improve outcomes in these aggressive melanomas.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1158/1078-0432.ccr-24-3164

Authors

More by this author
Role:
Author
ORCID:
0009-0000-3456-200X
More by this author
Role:
Author
ORCID:
0000-0001-5596-7196
More by this author
Role:
Author
ORCID:
0000-0002-9757-4937
More by this author
Role:
Author
ORCID:
0000-0002-5602-3311
More by this author
Role:
Author
ORCID:
0009-0009-0513-4319


More from this funder
Funder identifier:
https://ror.org/01h0zpd94
Grant:
U21A20379


Publisher:
American Association for Cancer Research (AACR)
Journal:
Clinical Cancer Research More from this journal
Volume:
31
Issue:
12
Pages:
2495–2514
Place of publication:
United States
Publication date:
2025-04-07
Acceptance date:
2025-04-03
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
Pmid:
40192737


Language:
English
Pubs id:
2117089
Local pid:
pubs:2117089
Deposit date:
2025-05-01
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP